Viva Biotech Holdings

As of December 31, 2025, Viva Biotech Holdings carries a market capitalization of 413.95M, placing it among publicly traded companies globally. Its enterprise value stands at 444.58M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Viva Biotech Holdings's next confirmed earnings release is scheduled for April 1, 2027.

As of December 31, 2025, Viva Biotech Holdings has 2.11B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Viva Biotech Holdings maintains a current ratio of 1.51, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Viva Biotech Holdings's stock has declined approximately 44.81% over the past 52 weeks. The 50-day moving average sits at 0.16, while the 200-day moving average is 0.18.

As of December 31, 2025, Viva Biotech Holdings holds 132.52M in cash and equivalents against 161.95M in total debt, resulting in a net debt position of 25.80M. Total book value stands at 486.44M, with working capital of 87.27M providing operational flexibility.